Aman Dalal, MD
Infectious Disease · Scottsdale, AZNPI 1750595575
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,460 of the $21,927 with a category attached, or 70.5%. Merck accounts for 75.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $8,600 and has fallen 91.1% since, to $762 in 2025. Among infectious disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $76.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$16K
- Melinta Therapeutics, LLC$2K
- Gilead$1K
- Mayne Pharma Commercial LLC$461
- AbbVie$354
- Insmed, Inc.$285
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$15,46071%
- Travel & lodging$1,5197%
- Food & beverage$4,93122%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 64 | $16,456 |
| Melinta Therapeutics, LLC | 17 | $2,217 |
| Gilead | 69 | $1,023 |
| Mayne Pharma Commercial LLC | 41 | $461 |
| AbbVie(2 entities) | 22 | $354 |
| Insmed, Inc. | 14 | $285 |
| Paratek Pharmaceuticals, Inc. | 16 | $254 |
| Viiv Healthcare Company | 10 | $212 |
| La Jolla Pharmaceutical Company | 6 | $122 |
| Astellas Pharma US Inc | 5 | $89 |
| Aimmune Therapeutics, Inc. | 4 | $88 |
| Johnson & Johnson | 3 | $61 |
| Shionogi Inc | 2 | $43 |
| Napo Pharmaceuticals Inc | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $32 |
| Nabriva Therapeutics, PLC | 2 | $32 |
| CSL Behring | 1 | $31 |
| Vyera Pharmaceuticals, LLC | 2 | $31 |
| Theratechnologies Inc. | 1 | $19 |
| Optinose US, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Echosens North America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,927 in reported general payments places this provider in the 95th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 78 | $319,857 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 15 | $119,974 |
| ErtapenemErtapenem Sodium | 191 | $86,418 |
| Daptomycin | 53 | $62,171 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $46,345 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $36,365 |
| TivicayDolutegravir Sodium | 13 | $28,579 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $27,881 |
| Meropenem | 68 | $21,772 |
| Vancomycin Hcl | 128 | $18,201 |
| Voriconazole | 52 | $11,965 |
| Fluconazole | 154 | $10,145 |
| CeftriaxoneCeftriaxone Sodium | 108 | $7,329 |
| Cefepime Hcl | 39 | $4,486 |
| Fosfomycin Tromethamine | 15 | $4,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,023 | $467,712106 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $212 | $64,94426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 146 infectious disease providers in Arizona.
Other infectious disease in Scottsdale
- Edward CachayScottsdale$26K
- Laura SchroederScottsdale$12K
- Sandhya NagarakantiScottsdale$7K
- Jamilah ShubeilatScottsdale$2K
- Andrew WallaceScottsdale$860
- Ahmad AldeiriScottsdale$799
- Jacob OommenScottsdale$743
- Omar GonzalezScottsdale$569
- Thanes VanigPhoenix$258K
- Anita KohliChandler$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.